Okta, Inc. Class A OKTA 深 滬
已收盤 01-09 16:00:00 美东时间
92.23
-1.700
-1.81%
華盛通- 最 高94.25
- 今 開94.25
- 成交量 182.17万股
- 最 低 91.57
- 昨 收 93.93
- 總市值 161.40亿
- 52周最高 127.567
- 市盈率 靜 1615.24
- 換手率 1.04%
- 52周最低 75.05
- 委 比 69.02%
- 總股本 1.75亿
- 歷史最高 294.00
- 量 比 0.71
- 振 幅 2.85%
- 歷史最低 21.55
- 每 手 1
- 風險率 10.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
RBC Capital Maintains Outperform on Okta, Raises Price Target to $108
RBC Capital analyst Matthew Hedberg maintains Okta (NASDAQ:OKTA) with a Outperform and raises the price target from $97 to $108.
01-06 00:10
4 stocks to watch on Monday: NVO, PANW, OKTA, TWLO
Stock index futures were higher before the bell on Monday as investors assessed the implications of the U.S. operation in Venezuela that removed President Nicolás Maduro from Caracas. Here are four st...
01-05 21:56
Okta shares are trading higher after the company announced a $1 billion share repurchase program.
Okta shares are trading higher after the company announced a $1 billion share r...
01-05 21:17
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
跑输纳指22%后，BTIG押注2026安全软件V型反转：Zscaler(ZS.US)、Netskope(NTSK.US)双雄称霸
BTIG认为，2026年上半年在安全与基础设施软件板块，大型股首选Zscaler(ZS.US)，中小盘股首选Netskope(NTSK.US)。该机构看好的其他...
2025-12-15 10:56
Okta's Sales Overhaul Pays Off As AI Security Hype Builds: Analyst
Okta's sales reorganization boosts productivity, leading analyst to maintain Buy rating. AI security and product momentum show promise.
2025-12-13 01:06
Needham Reiterates Buy on Okta, Maintains $110 Price Target
Needham analyst Mike Cikos reiterates Okta (NASDAQ:OKTA) with a Buy and maintains $110 price target.
2025-12-12 18:28
